BMSSC
KROS icon

B. Metzler seel. Sohn & Co’s Keros Therapeutics KROS Stock Holding History

B. Metzler seel. Sohn & Co’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-16,103
Closed -$935K – 771
2024
Q3 		$935K Hold
16,103
– – 0.01% 557
2024
Q2 		$736K Hold
16,103
– – 0.01% 581
2024
Q1 		$1.07M Hold
16,103
– – 0.01% 513
2023
Q4 		$640K Buy
16,103
+1,952
+14% +$61.2K 0.01% 574
2023
Q3 		$451K Sell
14,151
-12,105
-46% -$452K 0.01% 593
2023
Q2 		$1.05M Buy
26,256
+13,940
+113% +$611K 0.01% 481
2023
Q1 		$526K Buy
12,316
+890
+8% +$45K 0.01% 548
2022
Q4 		$549K Buy
+11,426
New +$534K 0.01% 540

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

B. Metzler seel. Sohn & Co's KROS Position: Q4 2024 in Review

B. Metzler seel. Sohn & Co sold out of Keros Therapeutics (KROS) in Q4 2024, closing a stake of 16,103 shares — an estimated $935K sold.

B. Metzler seel. Sohn & Co first reported a position in KROS in Q4 2022 and held it in 8 quarters. The position peaked at $1.07M in Q1 2024. 161 funds tracked by Wall St. Rank hold KROS as of Q4 2024.

  • B. Metzler seel. Sohn & Co reported no remaining Keros Therapeutics position as of Q4 2024 after selling out during the quarter.
  • B. Metzler seel. Sohn & Co sold 16,103 Keros Therapeutics shares in Q4 2024, an estimated $935K.
  • B. Metzler seel. Sohn & Co first reported a position in Keros Therapeutics in Q4 2022 and held it in 8 quarters.
  • B. Metzler seel. Sohn & Co's Keros Therapeutics position peaked at $1.07M in Q1 2024.
  • 161 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2024.

Based on B. Metzler seel. Sohn & Co's 13F filing for Q4 2024, filed 12 Feb 2025.